- Home
- VBIO vs DRCT Comparison
VBIO vs DRCT Comparison
Compare VBIO & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VBIO | DRCT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VBIO | DRCT |
|---|---|---|
| Price | $2.30 | $1.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 23.1M | 10.4K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $780,000.00 | ★ $34,694,000.00 |
| Revenue This Year | N/A | $5.42 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.11 | $0.04 |
| 52 Week High | $4.14 | $7.21 |
Technical Indicators
Market Signals| Indicator | VBIO | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 23.93 |
| Support Level | $0.30 | $1.52 |
| Resistance Level | $4.14 | $1.96 |
| Average True Range (ATR) | 0.59 | 0.13 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 51.91 | 2.35 |
Price Performance
Historical ComparisonAbout VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.